• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
YUAN Shanhui,JI Hui,LU Yuntao,TANG Hui.Clinical research progress of novel μ-receptor agonists oliceridine and tegileridine in moderate to severe postoperative pain[J].Journal Of Pharmaceutical Research,2025,44(6):580-588[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2721times   Download 810次 QR Code for this article
Scan with your phone!
新型μ受体偏向性激动剂奥赛利定和泰吉利定在治疗术后中、重度疼痛的临床研究进展
袁善慧1,2,计慧1,2,陆云涛1,唐辉1,2
Font:Larger+|Default|Smaller-
(1.山东第一医科大学附属省立医院干细胞临床研究中心,山东 济南 250021;2.山东第一医科大学附属省立医院药学部,山东 济南 250021)
摘要:
疼痛被称为人类第五大生命体征,术后疼痛是发生率最高的疼痛之一,有效管理术后疼痛可为患者减轻负担,提高生活质量。阿片类药物虽是疼痛药物的基石,但呼吸抑制和耐受等限制了其临床应用。新型μ受体偏向性激动剂奥赛利定和泰吉利定的镇痛效果与吗啡相当且阿片类相关不良反应发生率低,是目前治疗术后中、重度疼痛且无替代疗法的新型镇痛药,可安全用于术后疼痛管理。为此本文将综述该类药物在术后中、重度疼痛临床研究中的疗效并探讨相关不良反应,以期为临床使用提供指导。
关键词:  奥赛利定  泰吉利定  临床试验  术后疼痛  不良反应
DOI:10.13506/j.cnki.jpr.2025.06.012
基金项目:国家自然科学基金项目(No.82102372);山东省立医院中青年创新人才基金项目
Publication Date:June 25, 2025
Clinical research progress of novel μ-receptor agonists oliceridine and tegileridine in moderate to severe postoperative pain
YUAN Shanhui1,2,JI Hui1,2,LU Yuntao1,TANG Hui1,2
(1.Stem Cell Clinical Institute, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250000, China;2.Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250000,China)
Abstract:
Pain is known as the fifth major vital sign of human beings, and postoperative pain is one of the most common types of pain. Effective management of postoperative pain can reduce the burden on patients and improve their quality of life. Opioids are the cornerstone of pain medication,but their clinical application is limited by respiratory depression and tolerance. The analgesic effects of the novel μ-receptor agonists oliceridine and tegileridine are comparable to morphine, and the incidence of opioid related adverse reactions is low.They are currently the new analgesics for the treatment of moderate to severe postoperative pain without alternative therapies, and can be safely used for postoperative pain management. This article will review the efficacy of this type of medication in clinical studies of moderate to severe postoperative pain and explore related adverse reactions,in order to provide guidance for clinical use.
Key words:  Oliceridine  Tegileridine  Clinical trials  Postoperative pain  Adverse reactions
Today's Visits:511    Total Visits:2383242
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.